SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs better-than-expected quarterly results and raised full-year revenue outlook sparked a sharp rally, with traders also pointing to growing backlog and quantum-computing demand. The upbeat reaction is tempered by debate over how much growth came from the SkyWater acquisition, as well as concerns about cash burn, dilution, and whether the gap-up can hold.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.17847452 USD and is down -3.32 over the last 24 hours. It is currently trading on 1894 active market(s) with $2,362,443,159.56 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sustained weakness and underperformance amid a broader crypto selloff are driving discussion, with traders also concerned that political uncertainty could delay the CLARITY Act. Many blame Ripples token supply and question XRPs utility, while others view the decline as a buying opportunity and continue accumulating.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,194,930.21672838. The last known price of Ethereum is 2,237.04719652 USD and is down -0.08 over the last 24 hours. It is currently trading on 14276 active market(s) with $10,523,558,576.48 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereums sharp pullback and choppy rebound dominate discussion, with bearish traders warning that rallies may fail while bullish traders view the weakness as a buying opportunity and point to support holding. The community remains divided over whether the recovery can continue or the broader crypto-market slide will resume.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Debate over Snowflakes consumption-based model is driving attention, with traders warning that tighter budgets could lead customers to cut queries, storage and AI workloads, pressuring usage-linked revenue. Others see the models flexibility as a source of recovery when spending improves, while dip buyers and bearish traders remain divided on the stocks direction.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertivs stronger-than-expected quarterly results, raised outlook and more than doubled organic orders sparked a sharp rally, reinforcing optimism about demand for its data-center power and cooling systems. Some traders see confirmation that AI infrastructure spending remains robust, while skeptics point to permitting delays, financing risks and uncertainty over whether orders will translate into delivered revenue.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladocs post-earnings rally is drawing attention as traders focus on improved profitability and cash generation, along with managements ability to address upcoming debt with cash rather than dilution. Bulls see a potential turnaround and speculate about a short squeeze, while skeptics point to declining revenue and continued weakness at BetterHelp.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Anticipation around clinical readoutsespecially CTX310s Phase 1b data and zugo-cel updatesis the dominant discussion, alongside debate over CRISPRs quarterly results and CASGEVYs commercial ramp. Traders are hopeful strong data could support a partnership or improve the pipeline outlook, while skeptics question whether positive developments will break the stocks long-running range.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins sharp, volatile selloff is driving attention to Strategy as a leveraged BTC proxy, with traders debating whether the weakness could deepen the stocks losses. Bears also cite dilution, preferred-stock obligations and a possible MSCI removal as risks, while bulls argue the pullback is a buying opportunity and look for a rebound.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Fords quarterly earnings beat and higher lower-end profit guidance are driving discussion, with bulls citing improving profitability and the dividend while skeptics question why the shares have struggled to hold gains and point to cost pressures and weak sales. Traders are also watching whether the stock can clear nearby resistance after the post-earnings move.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is drawing attention after quarterly results beat expectations, with Alani Nu growth and international expansion offsetting a decline in the flagship Celsius brand. Traders welcomed the beat and stock rebound, but some question how durable the growth is and point to weaker core-brand sales and compressed margins.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis

Kardigan, Inc. (Nasdaq: KARD), a precision cardiovascular company, today announced enrollment completion in the Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis (AS). The Company also shared insights from a pre-planned analysis of the trials baseline data, as well as new...

This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday

Analysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.read more...

Kardigan Announces Appointment of Kristin Reinke to its Board of Directors

Kardigan, Inc. (Nasdaq: KARD) (Kardigan), a precision cardiovascular company, announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committee. As part of the Boards public company evolution, Doug Giordano will be stepping down from...

Kardigan to Present at Two September Investor Conferences

Kardigan, Inc. (Nasdaq: KARD) (Kardigan or the Company), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments, will participate at the following conferences in September.2026 Cantor Global Healthcare...

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

Kardigan, Inc. (Nasdaq: KARD) (Kardigan or the Company), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments, today reported financial results from the second quarter ended June 30, 2026, and...

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Kardigan, Inc. (Nasdaq: KARD) (Kardigan), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced the closing of its initial public offering of an aggregate 28,750,000...

Kardigan Announces Pricing of Upsized Initial Public Offering

Kardigan, Inc. (Nasdaq: KARD) (Kardigan), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced the pricing of its initial public offering of 25,000,000 shares of common...

Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.

Kardigan Inc.

Bearish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Baird🏁 $KARD and said -- Initiating coverage with an Outperform rating and $43 price target. 
$CYTK EWTX BMY TNYA $MLYS AZN RCKT ALNY RHHBY TECX TENX MRK BAYRY IONS 
Baird added—We like Kardigan's three-asset precision-cardiology portfolio, anchored by danicamtiv's potential to improve heart function in familial/genetic DCM, where we believe the myosin activator mechanism is well-positioned for success (particularly in the sarcomeric core patients). 
 
In addition to danicamtiv, ataciguat in CAVS and tonlamarsen in ASH offer additional higher-risk higher-reward shots-on-goal and with Phase 2 readouts across all three programs expected 1H27, we see multiple opportunities for clinical validation (all three of which target high-unmet-need indications) to drive share-price appreciation.

Feed

News

Sentiment

Earnings

Fundamentals

Info

KARD Kardigan Inc.

Fundamentals

Latest KARD News